Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Add an action for ACON.US, or sign in to see your action list.
| Name | Title | Year Born |
|---|---|---|
| Dr. Jeffrey John Thramann M.D. | Executive Chairman | 1965 |
| Mr. Brent Ness | CEO, President & Director | 1967 |
| Mr. Gregory A. Gould CPA | Chief Financial Officer | 1966 |
| Mr. Ryan Bond | Chief Strategy Officer | 1972 |
| Date | Insider Name | Title | Transaction Type | Shares | Price | Value | SEC |
|---|---|---|---|---|---|---|---|
| Nov 26, 2025 | Brent Ness | N/A | Purchase | 10.00 | $6.20 | $62.00 | SEC |
Comprehensive raw data returned from the EOD Fundamentals API. Expand sections below to drill down.